Your Notifications
All done, no notifications

Lung Cancer Treatment Cost in Italy

USD 25000 - USD 65000

Affordable World-class Treatment - Accredited Hospitals - Free Treatment Plan in 24 Hrs

3
Days in Hospital
2-6 hrs
Procedure Time
70 - 90%
Success Rate
Lung Cancer Treatment: Cost, Procedure and Clinics | MediGence
JCI/ISO 100,000+ Patients 24X7 Coordinator Visa & Travel handled
Your all-in-one medical travel platform for treatment, recovery & care.

Get Your Personalised Treatment Plan in Just 24 Hours.

Share your details to receive a personalised treatment plan, estimated costs, hospital recommendations, and expert guidance, “completely free.”

Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact
Connect with an Expert

Your information is protected with HIPAA-compliant security standards. We only share your details with hospitals after your consent.

Estimated Treatment Cost
USD 25000 - USD 65000
All-inclusive • Hospital + Medications + Recovery Assistance + Dedicated Care Coordinator

International Quality. Affordable Care.

What's included in your Lung Cancer Treatment quote?

Lung Cancer Treatment
Personalised treatment plan including surgery, chemotherapy, radiotherapy, immunotherapy, or targeted therapy as recommended
Oncology team consultation
Pre-treatment evaluation, treatment planning, and post-treatment follow-up consultations
Hospital stay & supportive care
Inpatient care, nursing support, pain management, and recovery monitoring
Follow-up monitoring
Imaging, laboratory tests, treatment response assessment, and routine follow-up visits
Visa & medical-visa invite letter
Airport pickup & transfers

Cost of Lung Cancer Treatment in Major Cities of Italy

CityCost (USD)
milan $14,400 – $33,600 Explore More

Lung Cancer Treatment - Italy Vs the World

$0 - $0
$0 - $0
$4k - $20k
$8k - $12k
$8k - $22k
$8k - $20k
$10k - $50k
$10k - $26k
$17k - $27k
$18k - $42k
$20k - $100k
$20k - $28k
$30k - $60k
$30k - $100k
Dr. Shagufta Parveen
Author

Doctor of Pharmacy

3 Years of Experience

Dr. Shagufta Parveen is a Clinical researcher and medical writer with expertise in clinical pharmacology and pharmacotherapeutics. She holds a B.Pharm and Doctor of Pharmacy (Post-Baccalaureate) degree from Teerthanker Mahaveer University, Moradabad.

During her clinical stint at BLK-Max Super Speciality Hospital and Indraprastha Apollo Hospital, she gained hands-on experience in the Clinical Pharmacology Department. Combining scientific knowledge with strong medical writing skills, Dr. Shagufta develops evidence-based healthcare content, treatment guides, and patient education resources.

Her work focuses on simplifying complex medical concepts while maintaining scientific accuracy, helping readers better understand healthcare advancements and treatment options.

In addition to her writing expertise, she is actively involved in scientific research and has contributed to peer-reviewed publications.

Her research work is accessible through the following links:

https://scholar.google.com/citations?user=lMVK1eIAAAAJ&hl=en

https://carcinogenesis.com/index.php/JOC/article/view/870

https://carcinogenesis.com/index.php/JOC/article/view/868

https://wjpsronline.com/abstract/0000000760

View More
Dr Prateek Varshney
Reviewer

Surgical Oncologist

15 Years of Experience

Last Reviewed - June 2026

Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute.
View More

Need Help Choosing the Right Treatment? Talk to a Medical Advisor

Our dedicated Medical Patient Advisors are here to answer your questions, help you compare treatment options, estimate costs, and guide you through every step of your healthcare journey.

15 min
Average response time

Serving Patients Worldwide in Multiple Languages.

Lung cancer is a disease characterized by the uncontrolled division of cells in the lungs. Normally, cells divide and replicate as part of their normal function. However, sometimes mutations occur, causing cells to divide uncontrollably. These damaged cells form masses, or tumors, which can eventually impair the function of organs.

It refers to cancers that originate in the lungs, generally in the airways (bronchi or bronchioles) or the small air sacs (alveoli). Cancers that originate in other parts of the body and spread to the lungs are usually referred to by the location where they began. In such cases, your doctor may describe this condition as metastatic cancer to the lungs.

Moreover, It is the third most common Cancer in the USA and is caused by harmful cells present in the lungs that grow unchecked. Different types of treatment are Chemotherapy, Immunotherapy, Radiation, and Targeted drugs. Advancements in the treatment options are causing a significant decline in lung cancer deaths.

Types

Following are different kinds of Lung Cancer

  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for over 80% of cases. Adenocarcinoma and squamous cell carcinoma are two popular kinds of non-small cell lung cancer. Sarcomatoid and adenosquamous carcinomas are less prevalent.
  • Small cell lung cancer (SCLC) grows more rapidly and is more challenging to treat than NSCLC. It is often detected as a relatively small lung tumor that has already spread to other parts of the body. Specific types of SCLC include small cell carcinoma (also known as oat cell carcinoma) and combined small cell carcinoma.

Other Types of Cancer in the Lungs

Other cancers can originate in or around the lungs, such as

  • lymphomas (cancer in the lymph nodes)
  • sarcomas (cancer in the bones or soft tissue)
  • pleural mesothelioma (cancer in the lining of the lungs)

These cancers are treated differently and are usually not classified as lung cancer.

Lung Cancer Stages

It is important to determine the stage of lung cancer by finding out how far the cancer has spread, before initiating treatment of lung cancer.
The following are the four lung cancer stages of NSCLC:

  • Stage 1 lung cancer: Cancer is restricted to the lung
  • Stage 2 lung cancer: Cancer has spread to the nearby lymph nodes
  • Stage 3 lung cancer: (3a) Cancer is in the lung and the lymph nodes located on the same side (3b) Cancer is in the lung and has spread to lymph nodes on the opposite side
  • Stage 4 lung cancer: Cancer has spread to both the lungs and other organs and surrounding tissues
Explore Hospitals ( 4 )

milan, Italy

1350+ Beds · 185+ Procedures
SSN
Starting
USD 28000

milan, Italy

560+ Beds · 187+ Procedures
SSN
Starting
USD 25000

milan, Italy

430+ Beds · 185+ Procedures
SSN

milan, Italy

560+ Beds · 185+ Procedures
SSN
Starting
USD 25000

Get Your Lung Cancer Treatment
Plan in 24 hrs.

Our experienced Medical Patient Advisors have supported 100,000+ patients across 120+ countries with personalised treatment plans, hospital recommendations, cost estimates, and travel assistance, all free.

HIPAA-Compliant Data SecurityShared Only with Your Consent

Free Consultation No Obligation Personalized Treatment Plan Response Within 24 Hours

Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Your medical info is kept HIPAA-style confidential. We never share with hospitals without your consent.

Jenny Wilson
Your Dedicated Medical Patient Advisor
Treatment planning • Hospital coordination • Multilingual support • Response within 15 minutes.
Our Services to Better your Experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Patient Stories

Abdi Ali Osman : Lung Cancer Treatment In Turkey
Abdi Ali Osman
Abdi Ali Osman : Lung Cancer Treatment

A 50 year old patient from Somalia underwent Right Lung Resection surgery at Turkey's prestigious Medicana Camlica Hospital. Read his…

Frequently Asked Questions

The cost of lung cancer treatment in Italy is USD 18000 - 42000, which depends on several factors, including the type and stage of cancer, treatment modality (surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, or combination treatment), hospital charges, specialist fees, diagnostic tests, hospital stay, and follow-up care. Additional expenses may include molecular testing, PET-CT scans, medications, rehabilitation, and supportive care.

Choose a multidisciplinary cancer team led by experienced medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists, and pathologists. Look for hospitals with comprehensive cancer centres, advanced diagnostic facilities, tumour boards, molecular testing capabilities, and strong experience in treating lung cancer.

Patients may require CT scans, PET-CT, bronchoscopy, biopsy, pulmonary function tests, MRI (if indicated), blood tests, and molecular biomarker testing (such as EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, and PD-L1) to determine the most effective treatment plan.

Yes. Patients with advanced disease, medically inoperable tumours, or specific genetic mutations may be treated successfully using radiation therapy, chemotherapy, targeted therapy, immunotherapy, or combinations of these treatments without surgery.

Targeted therapy uses medications that attack specific genetic mutations found within cancer cells while minimising damage to healthy tissue. It is recommended for patients whose tumours test positive for actionable mutations such as EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, or NTRK.

Yes. Immunotherapy has become an important treatment option for many patients with non-small cell lung cancer, particularly those with high PD-L1 expression or advanced disease. It may be used alone or in combination with chemotherapy depending on tumour characteristics.

Follow-up usually includes regular physical examinations, CT scans, blood tests, and, when necessary, PET-CT imaging to monitor for recurrence, evaluate treatment response, and manage any long-term side effects in Italy. The frequency of follow-up depends on the cancer stage and the treatment received.

The success rate of lung cancer treatment is 60–80%, which depends on the cancer stage, tumour type (NSCLC or SCLC), genetic mutations, overall health, and response to treatment. Early-stage lung cancer has significantly better outcomes, while advanced therapies such as targeted therapy and immunotherapy have improved survival for many patients with advanced disease.

Advanced cancer centres may offer:
  • Video-Assisted Thoracoscopic Surgery (VATS)
  • Robotic-assisted thoracic surgery
  • Lobectomy, segmentectomy, pneumonectomy
  • Stereotactic Body Radiation Therapy (SBRT)
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Image-Guided Radiation Therapy (IGRT)
  • Proton Beam Therapy (available in selected centres)
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Molecular profiling (EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK)
  • Liquid biopsy
  • Precision oncology and multidisciplinary tumour board planning
  • Potential complications depend on the treatment received and may include infection, bleeding, pneumonia, fatigue, nausea, reduced lung function, shortness of breath, radiation-induced lung inflammation (pneumonitis), nerve injury, medication side effects, and recurrence of cancer. Early monitoring and supportive care help reduce these risks.

    Patients should gather all medical records, pathology reports, biopsy slides (if available), CT scans, PET-CT scans, bronchoscopy reports, pulmonary function tests, blood investigations, molecular testing results, and details of previous treatments. Smoking cessation, nutritional optimisation, and fitness evaluation may also be recommended before treatment.

    Yes. Most international cancer centres in Italy provide virtual consultations where specialists review pathology reports, imaging, genetic test results, and previous treatments before recommending a personalised treatment plan and estimated costs.

    Patients should carry:
  • Passport and travel documents
  • Histopathology and biopsy reports
  • PET-CT, CT scan, MRI, and X-ray images
  • Bronchoscopy reports
  • Molecular profiling reports
  • Blood investigations
  • Previous chemotherapy or radiation records
  • Medication and allergy list
  • Medical insurance documents (if applicable)
  • The required stay depends on the treatment plan. Surgery generally requires a shorter stay followed by recovery, while chemotherapy, radiation therapy, targeted therapy, or immunotherapy may require multiple visits over several weeks or months. The treating team will provide a personalised schedule.

    Recovery varies according to the treatment received. Patients undergoing minimally invasive surgery may recover within a few weeks, whereas major surgery, chemotherapy, or radiation therapy may require a longer recovery period. Follow-up imaging and rehabilitation are important for monitoring progress.

    Patients receive regular follow-up with imaging, blood tests, and clinical evaluations. Complications such as infection, breathing difficulties, treatment-related side effects, or recurrence are managed promptly by the multidisciplinary oncology team using medications, rehabilitation, interventional procedures, or additional therapies.

    International patients can upload their medical records through MediGence in Italy. The MediGence care team will arrange an online consultation with leading lung cancer specialists, recommend suitable cancer hospitals, provide personalized treatment plans and cost estimates, and assist with medical visas, travel, accommodation, hospital appointments, and end-to-end treatment coordination.

    Many countries offer internationally accredited cancer centres, experienced thoracic oncology specialists, advanced molecular diagnostics, precision oncology programmes, robotic surgery, immunotherapy, and comprehensive international patient services. Patients should compare hospitals based on expertise, technology, treatment outcomes, and multidisciplinary care.

    Treatment options may include:
  • Surgical resection (lobectomy, segmentectomy, pneumonectomy)
  • Video-Assisted Thoracoscopic Surgery (VATS)
  • Robotic thoracic surgery
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Radiation therapy (IMRT, IGRT, SBRT)
  • Proton Beam Therapy (selected centres)
  • Combined chemoradiation
  • Palliative and supportive care
  • Clinical trials for eligible patients
  • Not Sure About Your Treatment Plan? Get a Free Second Opinion

    Have your reports reviewed by independent oncology experts to help you make a confident treatment decision, all online within 48 hours.

    Upload Your Reports
    Free second opinion on your CAR-T plan